

Haydeh Payami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1956997/publications.pdf>

Version: 2024-02-01

71
papers

9,571
citations

76196

40
h-index

79541

73
g-index

79
all docs

79
docs citations

79
times ranked

12482
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. <i>Nature Genetics</i> , 2014, 46, 989-993.	9.4	1,685
2	Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. <i>Nature Genetics</i> , 2010, 42, 781-785.	9.4	692
3	Large-scale association analyses identify host factors influencing human gut microbiome composition. <i>Nature Genetics</i> , 2021, 53, 156-165.	9.4	676
4	Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. <i>Movement Disorders</i> , 2017, 32, 739-749.	2.2	649
5	Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations. <i>American Journal of Human Genetics</i> , 2005, 76, 672-680.	2.6	524
6	Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. <i>PLoS Genetics</i> , 2012, 8, e1002548.	1.5	495
7	Independent Predictors of Cognitive Decline in Healthy Elderly Persons. <i>Archives of Neurology</i> , 2002, 59, 601.	4.9	300
8	The Number of Trait Loci in Late-Onset Alzheimer Disease. <i>American Journal of Human Genetics</i> , 2000, 66, 196-204.	2.6	286
9	Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn's disease and Parkinson's disease. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	273
10	Meta-analysis of Parkinson's Disease: Identification of a novel locus, <i>RIT2</i> . <i>Annals of Neurology</i> , 2012, 71, 370-384.	2.8	264
11	Increased risk of Parkinson's disease in parents and siblings of patients. <i>Annals of Neurology</i> , 1994, 36, 659-661.	2.8	214
12	Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene <i>GRIN2A</i> as a Parkinson's Disease Modifier Gene via Interaction with Coffee. <i>PLoS Genetics</i> , 2011, 7, e1002237.	1.5	206
13	Cognitive Markers Preceding Alzheimer's Dementia in the Healthy Oldest Old. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 584-589.	1.3	172
14	SNCA Variant Associated With Parkinson Disease and Plasma α -Synuclein Level. <i>Archives of Neurology</i> , 2010, 67, 1350-6.	4.9	157
15	Association of Parkinson Disease with Structural and Regulatory Variants in the HLA Region. <i>American Journal of Human Genetics</i> , 2013, 93, 984-993.	2.6	145
16	Frequency of Tau Gene Mutations in Familial and Sporadic Cases of Non-Alzheimer Dementia. <i>Archives of Neurology</i> , 2001, 58, 383-7.	4.9	143
17	Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. <i>Npj Parkinson's Disease</i> , 2020, 6, 11.	2.5	140
18	Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease. <i>Movement Disorders</i> , 2018, 33, 793-804.	2.2	130

#	ARTICLE	IF	CITATIONS
19	Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. <i>Annals of Neurology</i> , 2007, 62, 137-144.	2.8	129
20	Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. <i>Movement Disorders</i> , 2008, 23, 88-95.	2.2	129
21	LRRK2 G2019S in Families with Parkinson Disease Who Originated from Europe and the Middle East: Evidence of Two Distinct Founding Events Beginning Two Millennia Ago. <i>American Journal of Human Genetics</i> , 2006, 79, 752-758.	2.6	111
22	Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2156-2163.	2.2	108
23	Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. <i>Annals of Neurology</i> , 2007, 61, 47-54.	2.8	105
24	SCA2 may present as levodopa-responsive parkinsonism. <i>Movement Disorders</i> , 2003, 18, 425-429.	2.2	99
25	Exploring gene-environment interactions in Parkinson's disease. <i>Human Genetics</i> , 2008, 123, 257-265.	1.8	92
26	Evidence for a Novel Late-Onset Alzheimer Disease Locus on Chromosome 19p13.2. <i>American Journal of Human Genetics</i> , 2004, 75, 398-409.	2.6	90
27	Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 564-568.	0.9	90
28	Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics. <i>Movement Disorders</i> , 2006, 21, 519-523.	2.2	84
29	Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. <i>Lancet Neurology</i> , The, 2006, 5, 917-923.	4.9	83
30	Familial Aggregation of Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 848-50.	4.9	75
31	The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors. <i>Journal of Human Genetics</i> , 2010, 55, 241-243.	1.1	70
32	Early-Onset Alzheimer Disease in Families With Late-Onset Alzheimer Disease. <i>Archives of Neurology</i> , 2006, 63, 1307.	4.9	62
33	Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2190-2195.	2.2	61
34	Genetic association between α -synuclein and idiopathic parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 1222-1230.	1.1	60
35	Evidence for More than One Parkinson's Disease-Associated Variant within the HLA Region. <i>PLoS ONE</i> , 2011, 6, e27109.	1.1	60
36	Analysis of the α -synuclein G209A mutation in familial Parkinson's disease. <i>Lancet</i> , The, 1998, 351, 37-38.	6.3	55

#	ARTICLE	IF	CITATIONS
37	Identification of a novel Parkinson's disease locus via stratified genome-wide association study. BMC Genomics, 2014, 15, 118.	1.2	53
38	Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Annals of Neurology, 1997, 42, 655-658.	2.8	52
39	parkin mutation analysis in clinic patients with early-onset Parkinson's disease. American Journal of Medical Genetics Part A, 2004, 129A, 44-50.	2.4	49
40	Cognitive and Motor Function in Long-Duration <i>PARKIN</i> -Associated Parkinson Disease. JAMA Neurology, 2014, 71, 62.	4.5	49
41	Identification of genetic modifiers of age-at-onset for familial Parkinson's disease. Human Molecular Genetics, 2016, 25, 3849-3862.	1.4	44
42	The emerging science of precision medicine and pharmacogenomics for Parkinson's disease. Movement Disorders, 2017, 32, 1139-1146.	2.2	42
43	Genetic Epidemiology of Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 1998, 11, 98-106.	1.2	38
44	Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. Neurogenetics, 2007, 8, 95-102.	0.7	34
45	Validity and Utility of a LRRK2 G2019S Mutation Test for the Diagnosis of Parkinson's Disease. Genetic Testing and Molecular Biomarkers, 2006, 10, 221-227.	1.7	32
46	Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	2.8	30
47	False-positive SCA8 gene test in a patient with pathologically proven multiple system atrophy. Annals of Neurology, 2005, 57, 462-463.	2.8	29
48	Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. Neuroscience Letters, 1999, 260, 193-195.	1.0	27
49	Evidence of linkage and association on chromosome 20 for late-onset Alzheimer disease. Neurogenetics, 2004, 5, 121-128.	0.7	27
50	Expression of α -synuclein in the human brain: relation to Lewy body disease. Molecular Brain Research, 2001, 92, 58-65.	2.5	26
51	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	2.8	26
52	One step closer to fixing association studies: evidence for age- and gender-specific allele frequency variations and deviations from Hardy-Weinberg expectations in controls. Human Genetics, 2005, 118, 322-330.	1.8	25
53	Lack of evidence for an association between <i>UCHL1</i> S18Y and Parkinson's disease. European Journal of Neurology, 2008, 15, 134-139.	1.7	25
54	Caffeine, creatine, GRIN2A and Parkinson's disease progression. Journal of the Neurological Sciences, 2017, 375, 355-359.	0.3	23

#	ARTICLE	IF	CITATIONS
55	Analysis of the LRRK2 G2019S Mutation in Alzheimer Disease. <i>Archives of Neurology</i> , 2006, 63, 156.	4.9	21
56	Segregation analysis of Parkinson disease. , 1998, 80, 410-417.		19
57	Accurate Determination of Ataxin-2 Polyglutamine Expansion in Patients with Intermediate-Range Repeats. <i>Genetic Testing and Molecular Biomarkers</i> , 2002, 6, 217-220.	1.7	18
58	The relationship between obsessive-compulsive symptoms and <i>PARKIN</i> genotype: The CORE-EPD study. <i>Movement Disorders</i> , 2015, 30, 278-283.	2.2	16
59	Exploring human-genome gut-microbiome interaction in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 74.	2.5	15
60	A linkage study of candidate loci in familial Parkinson's Disease. <i>BMC Neurology</i> , 2003, 3, 6.	0.8	14
61	Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson's Disease. A Perspective. <i>Neurotherapeutics</i> , 2014, 11, 111-116.	2.1	14
62	Plasticity-related gene 3 (<i>LPPR1</i>) and age at diagnosis of Parkinson disease. <i>Neurology: Genetics</i> , 2018, 4, e271.	0.9	12
63	DNA variants in <i>CACNA1C</i> modify Parkinson disease risk only when vitamin D level is deficient. <i>Neurology: Genetics</i> , 2016, 2, e72.	0.9	11
64	parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism. <i>BMC Neurology</i> , 2005, 5, 4.	0.8	10
65	Lack of evidence for maternal effect in familial Alzheimer's disease. <i>Genetic Epidemiology</i> , 1993, 10, 461-464.	0.6	9
66	Apolipoprotein E ϵ 4 Is Associated with Neuronal Loss in the Substantia nigra in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 437-441.	0.7	8
67	DBH ϵ 1021C \rightarrow T does not modify risk or age at onset in Parkinson's disease. <i>Annals of Neurology</i> , 2007, 62, 99-101.	2.8	7
68	Glutamate Receptor Gene <i>GRIN2A</i> , Coffee, and Parkinson Disease. <i>PLoS Genetics</i> , 2014, 10, e1004774.	1.5	7
69	Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease. <i>Genetic Epidemiology</i> , 2010, 34, 92-99.	0.6	6
70	Exclusion of dominant mutations within the FTDP-17 locus on chromosome 17 for Parkinson's disease. <i>Neuroscience Letters</i> , 1999, 272, 140-142.	1.0	4
71	Reply to correspondence from Inzelberg et al.??onset age of Parkinson disease?. <i>American Journal of Medical Genetics Part A</i> , 2002, 111, 461-461.	2.4	1